[{"id":"cf2cfcd4-c077-4397-9d63-381c2282ddc5","acronym":"TATCIST","url":"https://clinicaltrials.gov/study/NCT05219500","created_at":"2022-02-05T18:28:39.147Z","updated_at":"2025-02-25T15:12:35.305Z","phase":"Phase 2","brief_title":"Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I\u0026T of Castration-resISTant Prostate Cancer (TATCIST).","source_id_and_acronym":"NCT05219500 - TATCIST","lead_sponsor":"Fusion Pharmaceuticals Inc.","biomarkers":" MSI • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FPI-2265"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-13"}]